PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: CUSTOMER LANDSCAPE PART 07: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 08: MARKET SEGMENTATION BY MECHANISM OF ACTION • Market segmentation by mechanism of action • Comparison by mechanism of action • Calcium channel alpha-2-delta ligand - Market size and forecast 2018-2023 • SNRIs and TCAs - Market size and forecast 2018-2023 • Others - Market size and forecast 2018-2023 • Market opportunity by mechanism of action PART 09: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 10: MARKET TRENDS • Market trends PART 11: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 12: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • DAIICHI SANKYO COMPANY, LIMITED • Eli Lilly and Company • Johnson & Johnson Services, Inc. • Novartis AG • Pfizer Inc. PART 13: APPENDIX • Research methodology • List of abbreviations   Exhibit 01: Years in consideration Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Customer landscape Exhibit 19: Market share by geography 2018-2023 (%) Exhibit 20: Geographic comparison Exhibit 21: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 22: North America - Year-over-year growth 2019-2023 (%) Exhibit 23: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Europe - Year-over-year growth 2019-2023 (%) Exhibit 25: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Asia - Year-over-year growth 2019-2023 (%) Exhibit 27: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 28: ROW - Year-over-year growth 2019-2023 (%) Exhibit 29: Key leading countries Exhibit 30: Market opportunity Exhibit 31: Mechanism of action - Market share 2018-2023 (%) Exhibit 32: Comparison by mechanism of action Exhibit 33: Calcium channel alpha-2-delta ligand - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Calcium channel alpha-2-delta ligand - Year-over-year growth 2019-2023 (%) Exhibit 35: SNRIs and TCAs - Market size and forecast 2018-2023 ($ millions) Exhibit 36: SNRIs and TCAs - Year-over-year growth 2019-2023 (%) Exhibit 37: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 38: Others - Year-over-year growth 2019-2023 (%) Exhibit 39: Market opportunity by mechanism of action Exhibit 40: Decision framework Exhibit 41: Pipeline drugs for diabetic neuropathy Exhibit 42: Impact of drivers and challenges Exhibit 43: Biologics under development Exhibit 44: Vendor landscape Exhibit 45: Landscape disruption Exhibit 46: Vendors covered Exhibit 47: Vendor_analysis1 Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: DAIICHI SANKYO COMPANY, LIMITED - Vendor overview Exhibit 51: DAIICHI SANKYO COMPANY, LIMITED - Business segments Exhibit 52: DAIICHI SANKYO COMPANY, LIMITED - Organizational developments Exhibit 53: DAIICHI SANKYO COMPANY, LIMITED - Geographic focus Exhibit 54: DAIICHI SANKYO COMPANY, LIMITED - Segment focus Exhibit 55: DAIICHI SANKYO COMPANY, LIMITED - Key offerings Exhibit 56: Eli Lilly and Company - Vendor overview Exhibit 57: Eli Lilly and Company - Business segments Exhibit 58: Eli Lilly and Company - Organizational developments Exhibit 59: Eli Lilly and Company - Geographic focus Exhibit 60: Eli Lilly and Company - Segment focus Exhibit 61: Eli Lilly and Company - Key offerings Exhibit 62: Johnson & Johnson Services, Inc. - Vendor overview Exhibit 63: Johnson & Johnson Services, Inc. - Business segments Exhibit 64: Johnson & Johnson Services, Inc. - Organizational developments Exhibit 65: Johnson & Johnson Services, Inc. - Geographic focus Exhibit 66: Johnson & Johnson Services, Inc. - Segment focus Exhibit 67: Johnson & Johnson Services, Inc. - Key offerings Exhibit 68: Novartis AG - Vendor overview Exhibit 69: Novartis AG - Business segments Exhibit 70: Novartis AG - Organizational developments Exhibit 71: Novartis AG - Geographic focus Exhibit 72: Novartis AG - Segment focus Exhibit 73: Novartis AG - Key offerings Exhibit 74: Pfizer Inc. - Vendor overview Exhibit 75: Pfizer Inc. - Business segments Exhibit 76: Pfizer Inc. - Organizational developments Exhibit 77: Pfizer Inc. - Geographic focus Exhibit 78: Pfizer Inc. - Segment focus Exhibit 79: Pfizer Inc. - Key offerings Exhibit 80: Validation techniques employed for market sizing Exhibit 81: List of abbreviations

DAIICHI SANKYO COMPANY, LIMITED Eli Lilly and Company Johnson & Johnson Services, Inc. Novartis AG Pfizer Inc.